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Testing of rapidly growing species of mycobacteria (RGM) against antibacterial agents has been shown to have some clinical utility.
This work establishes the MICs of seven antimicrobial agents following the guidelines set forth by the Clinical and Laboratory
Standards Institute (CLSI) against eighteen isolates of Mycobacterium massiliense recovered from wound samples of patients
submitted to minimally invasive surgery such as arthroscopy and laparoscopy. The isolates showed susceptibility to amikacin
(MIC90 = 4µg/mL) and clarithromycin (MIC90 < 1µg/mL) but resistance to ciproﬂoxacin (MIC90 > 16µg/mL), doxycycline
(MIC90 > 32µg/mL), sulfamethoxazole (MIC90 > 128µg/mL), and tobramycin (MIC90 = 32µg/mL), and intermediate proﬁle to
cefoxitin (MIC90 = 64µg/mL).Therefore,wesuggestthattheantimicrobialsusceptibilitiesofanyclinicallysigniﬁcantRGMisolate
should be performed.
1.Introduction
Infections by rapidly growing mycobacteria (RGM) are
increasinginminimallyinvasivelysurgeriesworldwide[1–3].
Mycobacteriummassiliensehasbeenisolatedfrompacemaker
pocket infection, intramuscular injections, and post-video
surgicalinfections[1,2,4–6].Mycobacteriummassiliensewas
validated as a separate species from the M. chelonae abscessus
group in 2004 [4].
In Brazil, outbreaks caused by RGM have been reported
since 1998. The former outbreaks occurred following laser
in situ keratomileusis (surgery for myopia correction),
mesotherapy sessions (intradermal injections) or breast
implants. Likewise, in those outbreaks M. chelonae-abscessus
group was the main pathogen found [7, 8]. Recently, an
epidemic of surgical-site infections was reported in seven
diﬀerent regions of Brazil, and surprisingly it was shown to
be caused by a single clone of M. massiliense [1, 2, 9, 10].
RGM are intrinsically resistant to several antibiotic drugs
reducing the number of active drugs to treat infections
by these bacteria and therefore antimicrobial susceptibility
testing have been shown to improve the clinical outcome
[11–13]. For this reason, it is recommended that all clinically
signiﬁcant isolates should be tested against selected antimi-
crobial agents [14, 15].
The Clinical and Laboratory Standards Institute (CLSI)
recommends the standard broth microdilution method for
susceptibility testing of the Mycobacterium fortuitum group
(M. fortuitum, M. peregrinum, and M. fortuitum third
variant complex), Mycobacterium chelonae,a n dMycobac-
terium abscessus. The method and guidelines for interpre-
tation of results, on theoretical grounds, also should apply
to Mycobacterium mucogenicum, Mycobacterium smegma-
tis group (M. smegmatis, M. goodii, and M. wolinskyi),
and the clinically signiﬁcant, pigmented RGM; however,
data to support this are not currently available [16].
Being a recently classiﬁed RGM, M. massiliense suscep-
tibility testing guidelines are needed, and susceptibility
testing data from diﬀerent settings will contribute for this
goal.2 Minimally Invasive Surgery
The aim of this work was to examine the in vitro
susceptibilities of M. massiliense isolates from wound sam-
ples of patients with infection post-video surgeries such as
arthroscopy and laparoscopy at seven private hospitals of
Goiˆ ania, Goi´ as, Brazil.
2.MaterialsandMethods
2.1. Mycobacterial Strains. The patients were from seven
private hospitals in the city of Goiˆ ania, State of Goi´ as,
Brazil. Patient enrollment occurred between August 2005
and July 2007. Eighteen epidemic isolates of M. massiliense
were included in this study, after patients signed consent
agreement. The microorganisms were isolated from clinical
samples of 18 patients that presented signs and symp-
toms of localized infection after minimally invasive surgery
(arthroscopy or laparoscopy). M. massiliense strains were
identiﬁed to the species level by PCR-restriction digestion
of the hsp65 gene, pulsed-ﬁeld gel electrophoresis (PFGE)
comparisons, and rpoB partial gene sequencing [1]. Isolates
were maintained on Lowenstein-Jensen slants prior to being
tested and subcultured onto Mueller-Hinton plates at 35◦C
for3to5days.M.abscessusATCC19977wasusedasaquality
control strain.
2.2. Antimicrobial Agents and Microdilution Trays. Serial
twofold dilutions of antimicrobial solutions were added
to Mueller-Hinton broth to achieve ﬁnal concentrations
of antimicrobial agents (all from Sigma Aldrich, USA):
amikacin (2 to 128µg/mL), cefoxitin (4 to 256µg/mL),
ciproﬂoxacin (0,25 to 16µg/mL), clarithromycin (1 to
64µg/mL), doxycycline (0,5 to 32µg/mL), sulfamethoxazole
(2 to 128µg/mL), and tobramycin (0,5 to 32µg/mL) and
added across the 96-well plates.
2.3. Susceptibility Testing. Minimal inhibitory concentra-
tions (MICs) of all tested drugs were determined by the
broth microdilution method according to the guidelines
described by the CLSI [16]. The ﬁnal inoculum size was
between 104 and 105 CFU/mL. Inoculated plates were sealed
inside plastic bags and incubated at 35◦C. All tests were
performed in triplicate and the MICs were read at 72h.
The susceptibility categories of all antimicrobial agents were
determined according to the breakpoints recommended by
CLSI [16].
3. Results andDiscussion
Eighteen isolates of M. massiliense were recovered from
wound samples of patients submitted to minimally inva-
sive surgery such as arthroscopy (n = 14, 77.8%) and
laparoscopy (n = 4, 22.2%).
All 18 strains tested were susceptible to amikacin (MIC90
= 4µg/mL) and clarithromycin (MIC90 < 1µg/mL) but
resistant to ciproﬂoxacin (MIC90 > 16µg/mL), doxycy-
cline (MIC90 > 32µg/mL), sulfamethoxazole (MIC90 >
128µg/mL), and tobramycin (MIC90 = 32µg/mL). All
Table 1: Antimicrobial susceptibility of 18 Mycobacterium mas-
siliense strains recovered from wound infections after arthroscopic
and laparoscopic surgeries during an outbreak in Goiˆ ania, Goi´ as,
Brazil.
Antimicrobial MIC50 MIC90 %
Amikacin <2 4 100 (S)
Cefoxitin 32 64 100 (I)
Ciproﬂoxacin >16 >16 100 (R)
Clarithromycin <1 <1 100 (S)
Doxycycline >32 >32 100 (R)
Sulfamethoxazole >128 >128 100 (R)
Tobramycin >32 >32 100 (R)
Allresults weredeterminedbybrothmicrodilutionmethod;I:Intermediate;
R:resistant;S:susceptible;CIM50:theMICcapableofpreventingthegrowth
of 50% of the isolates; MIC90:t h eM I Cc a p a b l eo fp r e v e n t i n gt h eg r o w t ho f
90% of the isolates.
isolates had intermediate MICs for cefoxitin (MIC90 =
64µg/mL). The results are summarized in Table 1.
RGM are intrinsically resistant to the antibiotics used for
tuberculosistreatment,consequentlypatientstreatmentwith
antituberculosis drugs for infection with those bacteria may
become compromised [17]. Infections by RGM that have
adequatelyandearlyidentiﬁcationofthemicroorganismwill
have a better result outcome [18]. Susceptibility testing is
a powerful tool in order to point for the use of the most
eﬀective drug and consequently enhancing the treatment
success rate.
Our susceptibility proﬁle results corroborate with those
of Ad´ ekambi et al. [4], except for the elevated MIC values
encountered for doxycycline. In regard to this particular
drug, other groups have reported similar ﬁndings [2, 6, 9].
This ﬁnding strengthen the idea that doxycycline should not
be used as a diﬀerentiation marker between M. massiliense
and M. abscessus [4].
According to CLSI [16], results for tobramycin should
not be reported for the M. fortuitum or M. abscessus groups,
as the treatment with this drug will only be superior to
amikacin in infections caused by M. chelonae.N os u s c e p t i -
bility testing recomendation is avaliable for M. massiliense
yet but, according to our data, this drug should not be
used, as all isolates were resistant to tobramycin. We have
encountered 100% of resistance among the strains tested for
sulfamethoxazole, similarly to the susceptibility reported for
M. chelonae e M. abscessus [16].
Clarithromycin has been indicated as the ﬁrst-line drug
of choice for the treatment of infections caused by RGM
[14, 19] and is appropriate for M. massiliense as well,
as all of the strains tested for this drug in our study
were susceptible. Koh et al. (2010) compared treatment
outcomes of patients infected with either M. abscessus or
M. massiliense and concluded that treatment response rates
to combination antibiotic therapy including clarithromycin
were much higher in patients with M. massiliense than in
those with M. abscessus lung disease [20].
Acquired resistance to clarithromycin has been reported
with a rate of 2.3% in patients receiving monotherapy [21]Minimally Invasive Surgery 3
and one death have been reported due to infection with
a resistant strain [22] .Ap r e v i o u sm o n o t h e r a p yt r i a lo f
clarithromycin for cutaneous disease caused by M. chelonae
in immunosuppressed patients (all patients were on corti-
costeroids) resulted in acquired resistance among isolates
from 1 of 10 (10%) patients with disseminated disease
and none of 4 (0%) patients with localized disease [23].
Because of the risks relative to resistance development, it has
been recommended the association of a second drug in the
treatment for infections with these bacteria. Amikacin seems
a good candidate, as in our study all strains were susceptible
to this drug.
Another drug that is associated with clarithromycin to
treat infections with RGM is cefoxitin [24], however our
results showed that M. massiliense isolates presented an
intermediary susceptibility to this drug. The diﬀerent proﬁle
of susceptibilities found in our study and others stress
the need for the proper RGM identiﬁcation followed by a
drug susceptibility screening in order to provide the most
appropriate antibiotic treatment.
The treatment of serious infections with RGM is a
problem and limited by the small number of available
drugs with activity at clinically achievable levels in tissue
or/and blood. Each species and strain must be individually
evaluated, and it is advisable always to perform in vitro
sensitivity tests before using the drug for human therapy
[25].
4. Conclusions
In conclusion, this study found that the MICs were higher
for M. massiliense when tested cefoxitin, ciproﬂoxacin,
doxycycline, sulfamethoxazole and tobramycin. Therefore,
amikacin and clarithromycin were active against M. mas-
siliense strains isolated in our study.
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